Focus:
Russian pharmaceutical serialisation requirements that will take effect in the new year are proving burdensome for manufacturers to implement but experts say the industry can benefit from the infrastructure investment...
The approved uses of immuno-oncology drugs lag behind the available data and lag behind the current situations in which clinicians will want to use the therapies.
Final data from BMS's Phase III CheckMate-227, Part 1 study was presented at the European Society of Medical Oncology conference in September.
Results demonstrated that first-line treatment of patients with advanced non-small cell lung cancer and high programmed cell death ligand-1 expression who used Roche’s Tecentriq monotherapy resulted in improved overall survival...
One speaker stated that in 2017, less than 50% of oncologists were prescribing biosimilars, primarily due to concerns regarding immunogenicity and extrapolation.
Merck & Co and Otsuka Holdings’ Keytruda is forecast to bring annual revenue of $22.2bn by 2025, figures from the GlobalData Pharma Intelligence Center Drug Sales and Consensus Forecast database show.
The markets of the Asia-Pacific are experiencing an increase in HSCT rates and will need to be ready for the added burden of HSCT-related issues such as respiratory syncytial virus...
Eastern equine encephalitis is an arbovirus — a virus that is transmitted by insects and ticks — found in the northeast of the US, along the Great Lakes, as well...
GlobalData believes the acquisition of worldwide rights to Otezla is a strategic purchase for Amgen, helping it to remain current in a fiercely competitive psoriasis market.
The incidence of prostate cancer varies worldwide, and the variation in rates may be attributed to prostate-specific antigen testing, a prostate cancer screening test.
